RxDoctor Payments Data

Ben Lee, DO

Internal Medicine · Brighton, MINPI 1376884833

Payments from drug & device makers

$11,116in general payments, 2019–2025

Across 745 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$992
  • Amgen$586
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$11,111100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,116 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$229,139
Medicare patients
415
Services billed
19,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide197$317,960
EliquisApixaban178$229,579
JardianceEmpagliflozin124$181,188
MounjaroTirzepatide96$128,067
XareltoRivaroxaban110$123,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter123$121,716
TrulicityDulaglutide56$76,365
FarxigaDapagliflozin Propanediol56$73,889
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$50,917
JanuviaSitagliptin Phosphate35$46,854
EntrestoSacubitril/Valsartan28$39,250
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$35,823
PercocetOxycodone Hcl/Acetaminophen13$33,250
Soliqua 100-33Insulin Glargine/Lixisenatide29$23,621
Tresiba Flextouch U-200Insulin Degludec12$19,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,858$317,960197 claims
PfizerEliquis, Paxlovid$1,097$233,655198 claims
Lilly USA, LLCMounjaro, Trulicity$992$204,431152 claims
Boehringer IngelheimJardiance, Stiolto Respimat$457$190,302138 claims
GSKTrelegy Ellipta, Breo Ellipta$411$131,478146 claims
Johnson & JohnsonXarelto$542$123,375110 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,186$109,712105 claims
MerckJanuvia$76$46,85435 claims
NovartisEntresto$370$39,25028 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$253$23,62129 claims
AbbVieSynthroid$1,206$4,07856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Brighton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →